Results 301 to 310 of about 447,577 (315)

Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling

Cancer Cell, 2019
Minhong Shen, Yi-Zhou Jiang, Xinlei Sheng   +2 more
exaly  

EGFR

2017
openaire   +1 more source

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

Annals of Oncology, 2019
Christine M Parseghian, Jonathan M Loree, Van K Morris   +2 more
exaly  

Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

Cancer Cell, 2019
Maria TERESA Blasco, Osvaldo Graña-Castro, Carmen G Lechuga   +2 more
exaly  

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Ca-A Cancer Journal for Clinicians
Maxime Borgeaud, Timothee Olivier, Jair Bar   +2 more
exaly  

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing

Annals of Oncology, 2014
H A Yu, M D Hellmann, M G Kris
exaly  

Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach

Ca-A Cancer Journal for Clinicians
Jyoti Malhotra, Lauren Antrim
exaly  

Targeting the EGFR signaling pathway in cancer therapy

Expert Opinion on Therapeutic Targets, 2012
Parthasarathy Seshacharyulu, Moorthy P Ponnusamy, Dhanya Haridas   +2 more
exaly  

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Journal of Thoracic Oncology, 2015
Jianhua Zhan, Shaodong Hong, Yanna Tang   +2 more
exaly  

Targeting tumor suppressor gene co‐mutations in EGFR ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification

Ca-A Cancer Journal for Clinicians
Gilberto de Lima Lopes
exaly